These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

369 related articles for article (PubMed ID: 17242007)

  • 1. N-terminal pro-brain natriuretic peptide, but not high sensitivity C-reactive protein, improves cardiovascular risk prediction in the general population.
    Olsen MH; Hansen TW; Christensen MK; Gustafsson F; Rasmussen S; Wachtell K; Ibsen H; Torp-Pedersen C; Hildebrandt PR
    Eur Heart J; 2007 Jun; 28(11):1374-81. PubMed ID: 17242007
    [TBL] [Abstract][Full Text] [Related]  

  • 2. N-terminal brain natriuretic peptide predicted cardiovascular events stronger than high-sensitivity C-reactive protein in hypertension: a LIFE substudy.
    Olsen MH; Wachtell K; Nielsen OW; Hall C; Wergeland R; Ibsen H; Kjeldsen SE; Devereux RB; Dahlöf B; Hildebrandt PR
    J Hypertens; 2006 Aug; 24(8):1531-9. PubMed ID: 16877955
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiovascular risk prediction by N-terminal pro brain natriuretic peptide and high sensitivity C-reactive protein is affected by age and sex.
    Olsen MH; Hansen TW; Christensen MK; Gustafsson F; Rasmussen S; Wachtell K; Ibsen H; Torp-Pedersen C; Hildebrandt PR
    J Hypertens; 2008 Jan; 26(1):26-34. PubMed ID: 18090537
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New risk markers may change the HeartScore risk classification significantly in one-fifth of the population.
    Olsen MH; Hansen TW; Christensen MK; Gustafsson F; Rasmussen S; Wachtell K; Ibsen H; Torp-Pedersen C; Hildebrandt PR
    J Hum Hypertens; 2009 Feb; 23(2):105-12. PubMed ID: 18784734
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of the metabolic syndrome on the predictive values of new risk markers in the general population.
    Olsen MH; Hansen TW; Christensen MK; Gustafsson F; Rasmussen S; Wachtell K; Ibsen H; Torp-Pedersen C; Hildebrandt PR
    J Hum Hypertens; 2008 Sep; 22(9):634-40. PubMed ID: 18528412
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-sensitivity C-reactive protein is only weakly related to cardiovascular damage after adjustment for traditional cardiovascular risk factors.
    Olsen MH; Christensen MK; Hansen TW; Gustafsson F; Rasmussen S; Wachtell K; Borch-Johnsen K; Ibsen H; Jørgensen T; Hildebrandt P
    J Hypertens; 2006 Apr; 24(4):655-61. PubMed ID: 16531793
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relation of adiponectin and high-sensitivity C-reactive protein to pulse-wave velocity and N-terminal pro-B-type natriuretic peptide in the general population.
    Sung SH; Chuang SY; Sheu WH; Lee WJ; Chou P; Chen CH
    Am J Cardiol; 2009 May; 103(10):1411-6. PubMed ID: 19427438
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incremental value of high-sensitivity C-reactive protein and N-terminal pro-B-type natriuretic peptide for the prediction of postoperative cardiac events in noncardiac vascular surgery patients.
    Goei D; Hoeks SE; Boersma E; Winkel TA; Dunkelgrun M; Flu WJ; Schouten O; Bax JJ; Poldermans D
    Coron Artery Dis; 2009 May; 20(3):219-24. PubMed ID: 19322079
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amino-terminal pro-B-type natriuretic peptide and high-sensitivity C-reactive protein but not cystatin C predict cardiovascular events in male patients with peripheral artery disease independently of ambulatory pulse pressure.
    Skoglund PH; Arpegård J; Ostergren J; Svensson P
    Am J Hypertens; 2014 Mar; 27(3):363-71. PubMed ID: 24470529
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cutoff values of NT-proBNP for the prediction of low functional capacity, decreased ejection fraction and cardiovascular events in patients with heart failure.
    Koç M; Bozkurt A; Yildiray-Sahin D; Unal I; Acartürk E
    Cardiol J; 2009; 16(1):43-9. PubMed ID: 19130415
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Usefulness of combined high-sensitive C-reactive protein and N-terminal-probrain natriuretic peptide for predicting cardiovascular events in patients with suspected coronary artery disease.
    Huang PH; Lu TM; Wu TC; Lin FY; Chen YH; Chen JW; Lin SJ
    Coron Artery Dis; 2008 May; 19(3):187-93. PubMed ID: 18418236
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aortic valve sclerosis and albuminuria predict cardiovascular events independently in hypertension: a losartan intervention for endpoint-reduction in hypertension (LIFE) substudy.
    Olsen MH; Wachtell K; Bella JN; Palmieri V; Gerdts E; Smith G; Nieminen MS; Dahlöf B; Ibsen H; Devereux RB
    Am J Hypertens; 2005 Nov; 18(11):1430-6. PubMed ID: 16280277
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Usefulness of N-terminal pro-brain natriuretic Peptide and brain natriuretic peptide to predict cardiovascular outcomes in patients with heart failure and preserved left ventricular ejection fraction.
    Grewal J; McKelvie RS; Persson H; Tait P; Carlsson J; Swedberg K; Ostergren J; Lonn E
    Am J Cardiol; 2008 Sep; 102(6):733-7. PubMed ID: 18773998
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative impact of multiple biomarkers and N-Terminal pro-brain natriuretic peptide in the context of conventional risk factors for the prediction of recurrent cardiovascular events in the Heart Outcomes Prevention Evaluation (HOPE) Study.
    Blankenberg S; McQueen MJ; Smieja M; Pogue J; Balion C; Lonn E; Rupprecht HJ; Bickel C; Tiret L; Cambien F; Gerstein H; Münzel T; Yusuf S;
    Circulation; 2006 Jul; 114(3):201-8. PubMed ID: 16831981
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction of myocardial infarction by N-terminal-pro-B-type natriuretic peptide, C-reactive protein, and renin in subjects with cerebrovascular disease.
    Campbell DJ; Woodward M; Chalmers JP; Colman SA; Jenkins AJ; Kemp BE; Neal BC; Patel A; MacMahon SW
    Circulation; 2005 Jul; 112(1):110-6. PubMed ID: 15983245
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of N-terminal pro-B-natriuretic peptide, C-reactive protein, and creatinine clearance for prognosis in patients with known coronary heart disease.
    Rothenbacher D; Koenig W; Brenner H
    Arch Intern Med; 2006 Dec 11-25; 166(22):2455-60. PubMed ID: 17159010
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The value of N-terminal fragment of brain natriuretic peptide and tissue inhibitor of metalloproteinase-1 levels as predictors of cardiovascular outcome in the LIPID study.
    West MJ; Nestel PJ; Kirby AC; Schnabel R; Sullivan D; Simes RJ; Pollicino C; Lubos E; Münzel TF; White HD; Tonkin AM; Bickel C; Tiret L; Blankenberg S;
    Eur Heart J; 2008 Apr; 29(7):923-31. PubMed ID: 18296678
    [TBL] [Abstract][Full Text] [Related]  

  • 18. N-terminal pro brain natriuretic peptide is inversely related to metabolic cardiovascular risk factors and the metabolic syndrome.
    Olsen MH; Hansen TW; Christensen MK; Gustafsson F; Rasmussen S; Wachtell K; Borch-Johnsen K; Ibsen H; Jørgensen T; Hildebrandt P
    Hypertension; 2005 Oct; 46(4):660-6. PubMed ID: 16129819
    [TBL] [Abstract][Full Text] [Related]  

  • 19. N-terminal pro-B-type natriuretic peptide (NT-proBNP) in HIV-1 infected individuals on HAART.
    Berg T; Zdunek D; Stalke J; Dupke S; Baumgarten A; Carganico A; Hess G
    Eur J Med Res; 2007 Apr; 12(4):152-60. PubMed ID: 17509959
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-sensitivity C-reactive protein and N-terminal pro-B-type natriuretic peptide in patients with stable coronary artery disease: a prognostic study within the CLARICOR trial.
    Harutyunyan MJ; Mathiasen AB; Winkel P; Gøtze JP; Hansen JF; Hildebrandt P; Jensen GB; Hilden J; Jespersen CM; Kjøller E; Kolmos HJ; Gluud C; Kastrup J;
    Scand J Clin Lab Invest; 2011 Feb; 71(1):52-62. PubMed ID: 21108561
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.